Products
Ocriplasmin is commercially available as an injectable (Jetrea). It has been approved in many countries since 2014.
Structure and properties
Ocriplasmin is a recombinant and truncated derivative of the human proteolytic enzyme plasmin with a molecular weight of 27.2 kDa. It is produced by biotechnological methods.
Effects
Ocriplasmin (ATC S01XA22) has proteolytic properties on protein components of the vitreous and vitreoretinal interface.
Indications
For the treatment of vitreomacular traction, including that associated with macular hole.
Dosage
According to the SmPC. The drug is injected intravitreally (into the vitreous humor of the eye).
Contraindications
- Hypersensitivity
- Infections in or around the eye
For complete precautions, see the drug label.
Interactions
Administration of other drugs in the same eye with a small time interval is not recommended.
Adverse effects
Possible adverse effects include local reactions to the eye such as “mouches volantes,” eye pain, photopsia, and conjunctival hemorrhage.
